Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice

Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice

The goal of the present study was to determine the efficacy of osimertinib (AZD9291), a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of aggressive EGFR-mutant non-small cell lung cancer (NSCLC), compared to cisplatinum (CDDP) + pemetrexed (PEM)...

Full description

Bibliographic Details
Main Authors: Takashi Higuchi, Hiromichi Oshiro, Zhiying Zhang, Kentaro Miyake, Norihiko Sugisawa, Yuki Katsuya, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Ming Zhao, Michael Bouvet, Shree Ram Singh, Hiroyuki Tsuchiya, Robert M Hoffman
Format: Article
Language:English
Published: Elsevier 2019-04-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523319300336

Internet

http://www.sciencedirect.com/science/article/pii/S1936523319300336

Similar Items